Skip to search formSkip to main contentSkip to account menu

alemtuzumab Injection [Lemtrada]

National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

1.2 ML alemtuzumab 10 MG/ML Injection [Lemtrada]
InjectionLemtrada

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Alemtuzumab (Lemtrada®): nuevas restricciones de uso
Tras finalizar la evaluacion europea del balance beneficio-riesgo de alemtuzumab (Lemtrada®) se recomienda restringir la… 
2017
2017
Multiple Sclerosis Selective Targeting of T and B Cell Populations by Alemtuzumab in the Treatment of Multiple Sclerosis
U pstream targeting of both T and B cells is a rational therapeutic approach in multiple sclerosis (MS) in view of how both cell… 
2015
2015
Treatment Effects Maintained Over Five Years in Majority of Patients with Relapsing Remitting Multiple Sclerosis who Received Genzyme’s Lemtrada® (alemtuzumab) in Clinical Trials
  • 2015
  • Corpus ID: 58898003
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, a Sanofi company, today announced posit ive new five-year investigational data from…